Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

Core Insights - Spero Therapeutics, Inc. is focused on developing tebipenem HBr, an investigational oral carbapenem aimed at treating complicated urinary tract infections (cUTI), including pyelonephritis [1] Group 1: Clinical Development - The Phase 3 trial (PIVOT-PO) for tebipenem HBr has successfully met its primary endpoint and was stopped early due to positive results [1]